2024-03-29T14:10:44Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/1243122021-11-22T12:50:20Zcom_10261_22com_10261_1col_10261_275
2015-11-02T13:13:19Z
urn:hdl:10261/124312
Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients
Benitez-Buelga, Carlos
Carrillo, Jaime
Perona Abellón, Rosario
Benítez, Javier
European Commission
European Research Council
Instituto de Salud Carlos III
Centro de Investigación Biomédica en Red Enfermedades Raras (España)
Ministerio de Ciencia e Innovación (España)
Ministerio de Economía y Competitividad (España)
Fundación Botín
Hermann-Kober Foundation
Eli Lilly and Company
Instituto de Salud Carlos III
Telomerase
Sporadic breast cancer
Familial breast cancer
Telomere length
Chemotherapy
et al.
Recently, we observed that telomeres of BRCA1/2 mutation carriers were shorter than those of controls or sporadic breast cancer patients, suggesting that mutations in these genes might be responsible for this event. Given the contradictory results reported in the literature, we tested whether other parameters, such as chemotherapy, could be modifying telomere length (TL). We performed a cross-sectional study measuring leukocyte TL of 266 sporadic breasts cancer patients treated with first-line chemotherapy, with a median follow-up of 240 days. Additionally, we performed both cross-sectional and longitudinal studies in a series of 236 familial breast cancer patients that included affected and non-affected BRCA1/2 mutation carriers. We have measured in leukocytes from peripheral blood: the TL, percentage of short telomeres (<3 kb), telomerase activity levels and the annual telomere shortening speed. In sporadic cases we found that chemotherapy exerts a transient telomere shortening effect (around 2 years) that varies depending on the drug combination. In familial cases, only patients receiving treatment were associated with telomere shortening but they recovered normal TL after a period of 2 years. Chemotherapy affects TL and should be considered in the studies that correlate TL with disease susceptibility.
2015-11-02T13:13:19Z
2015-11-02T13:13:19Z
2014
2015-11-02T13:13:19Z
artículo
Breast Cancer Research and Treatment 149(2): 385-394 (2014)
http://hdl.handle.net/10261/124312
10.1007/s10549-014-3246-6
http://dx.doi.org/10.13039/501100000780
http://dx.doi.org/10.13039/501100000781
http://dx.doi.org/10.13039/501100004587
http://dx.doi.org/10.13039/501100004837
http://dx.doi.org/10.13039/501100003329
http://dx.doi.org/10.13039/501100006373
http://dx.doi.org/10.13039/100004312
25528024
eng
Sí
info:eu-repo/grantAgreement/EC/FP7/232854
closedAccess
Springer